449 related articles for article (PubMed ID: 30986486)
1. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of a
Rousseau C; Le Thiec M; Ferrer L; Rusu D; Rauscher A; Maucherat B; Frindel M; Baumgartner P; Fleury V; Denis A; Morel A; Varmenot N; Debeaupuis E; Campion L; Kraeber-Bodéré F
Prostate; 2019 Sep; 79(13):1514-1522. PubMed ID: 31421657
[TBL] [Abstract][Full Text] [Related]
4.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
5. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.
Sathianathen NJ; Butaney M; Konety BR
World J Urol; 2019 Jul; 37(7):1239-1249. PubMed ID: 30003375
[TBL] [Abstract][Full Text] [Related]
6. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
7. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
9. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract][Full Text] [Related]
10. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
11.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
12. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
13. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Leitsmann C; Thelen P; Schmid M; Meller J; Sahlmann CO; Meller B; Trojan L; Strauss A
Int Braz J Urol; 2019; 45(3):459-467. PubMed ID: 30901173
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
16. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
18. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
19. Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study.
Mattiolli AB; Santos A; Vicente A; Queiroz M; Bastos D; Herchenhorn D; Srougi M; Peixoto FA; Morikawa L; da Silva JLF; Etchebehere E
Int Braz J Urol; 2018; 44(5):892-899. PubMed ID: 30088720
[TBL] [Abstract][Full Text] [Related]
20. Exploratory cost-effectiveness analysis of
Gordon LG; Elliott TM; Joshi A; Williams ED; Vela I
Clin Exp Metastasis; 2020 Apr; 37(2):305-312. PubMed ID: 32064552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
